Hyderabad based life science company Suven Life Sciences Ltd has presented several data from Suven's own portfolio of investigational new chemical entitles (NCEs) at Neuroscience 2007 meeting being held at San Diego, USA from Nov 3-7.

Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30 thousand Neuro Scientists from all over the world covering all major Pharma and Academic research Institutions would attend this meeting.

Suven is presenting new data of their New Chemical Entities (NCE's) in the five promising areas of neuroscience viz. alzheimer's, schizophrenia, parkinson, sleep and obesity diseases for which Suven was granted 9 product patents (2 from EU, 3 from India, 2 from Australia and 2 from New Zealand). These areas present significant unmet medical need for which current treatment options are insufficient. Suven has a number of programms in each of these areas, focusing on novel approaches that may lead to the development of new therapies for patients. All these programmes belong to Suven's in house drug discovery programme and do not involve any partner or collaborator.

Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven's discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven's CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like alzheimer's schizophrenia, depression, cognitive disorders, sleep, neurodegeneration and obesity through CNS targets.